Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 10.0
(2.35%)
USD 10.0
(2.35%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 9.55 Billion USD | -2.03% |
| 2023 | 33.53 Billion USD | -5.48% |
| 2022 | 35.47 Billion USD | 6.24% |
| 2021 | 33.39 Billion USD | -16.81% |
| 2020 | 40.14 Billion USD | 138.42% |
| 2019 | 16.83 Billion USD | 16.94% |
| 2018 | 14.39 Billion USD | 11.3% |
| 2017 | 12.93 Billion USD | -32.02% |
| 2016 | 19.02 Billion USD | 32.3% |
| 2015 | 14.38 Billion USD | 218.91% |
| 2014 | 4.51 Billion USD | -10.64% |
| 2013 | 5.04 Billion USD | -6.4% |
| 2012 | 5.39 Billion USD | 123.83% |
| 2011 | 2.4 Billion USD | 0.33% |
| 2010 | 2.4 Billion USD | 2.13% |
| 2009 | 2.35 Billion USD | 65.58% |
| 2008 | 1.41 Billion USD | 61.63% |
| 2007 | 878.5 Million USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 440.7 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | -100.0% |
| 1992 | 22.9 Million USD | -82.0% |
| 1991 | 127.2 Million USD | -15.14% |
| 1990 | 149.9 Million USD | -2.03% |
| 1989 | 153 Million USD | -13.12% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 33.66 Billion USD | -2.78% |
| 2024 Q1 | 33.73 Billion USD | 0.61% |
| 2024 Q4 | 9.55 Billion USD | -2.41% |
| 2024 Q2 | 34.62 Billion USD | 2.64% |
| 2023 Q2 | 37.57 Billion USD | 5.81% |
| 2023 FY | 33.53 Billion USD | -5.48% |
| 2023 Q1 | 35.51 Billion USD | 0.1% |
| 2023 Q3 | 36.43 Billion USD | -3.03% |
| 2023 Q4 | 33.53 Billion USD | -7.97% |
| 2022 FY | 35.47 Billion USD | 6.24% |
| 2022 Q4 | 35.47 Billion USD | -4.83% |
| 2022 Q2 | 37.53 Billion USD | -1.77% |
| 2022 Q1 | 38.21 Billion USD | 14.44% |
| 2022 Q3 | 37.27 Billion USD | -0.69% |
| 2021 Q3 | 40.11 Billion USD | -1.34% |
| 2021 Q4 | 33.39 Billion USD | -16.75% |
| 2021 Q1 | 40.81 Billion USD | 1.69% |
| 2021 Q2 | 40.65 Billion USD | -0.41% |
| 2021 FY | 33.39 Billion USD | -16.81% |
| 2020 FY | 40.14 Billion USD | 138.42% |
| 2020 Q1 | 41.03 Billion USD | 143.73% |
| 2020 Q2 | 40.84 Billion USD | -0.46% |
| 2020 Q3 | 40.72 Billion USD | -0.31% |
| 2020 Q4 | 40.14 Billion USD | -1.43% |
| 2019 FY | 16.83 Billion USD | 16.94% |
| 2019 Q3 | 17.6 Billion USD | -2.39% |
| 2019 Q4 | 16.83 Billion USD | -4.39% |
| 2019 Q2 | 18.04 Billion USD | 12.83% |
| 2019 Q1 | 15.99 Billion USD | 11.06% |
| 2018 FY | 14.39 Billion USD | 11.3% |
| 2018 Q1 | 14 Billion USD | 8.27% |
| 2018 Q2 | 15.67 Billion USD | 11.9% |
| 2018 Q3 | 15.04 Billion USD | -4.01% |
| 2018 Q4 | 14.39 Billion USD | -4.29% |
| 2017 Q1 | 18.87 Billion USD | -0.82% |
| 2017 FY | 12.93 Billion USD | -32.02% |
| 2017 Q4 | 12.93 Billion USD | -32.67% |
| 2017 Q3 | 19.21 Billion USD | 1.58% |
| 2017 Q2 | 18.91 Billion USD | 0.21% |
| 2016 Q3 | 13.52 Billion USD | -3.57% |
| 2016 Q2 | 14.02 Billion USD | -1.76% |
| 2016 FY | 19.02 Billion USD | 32.3% |
| 2016 Q4 | 19.02 Billion USD | 40.69% |
| 2016 Q1 | 14.27 Billion USD | -0.74% |
| 2015 Q4 | 14.38 Billion USD | -11.47% |
| 2015 Q2 | 17.06 Billion USD | 17.43% |
| 2015 Q1 | 14.53 Billion USD | 222.17% |
| 2015 FY | 14.38 Billion USD | 218.91% |
| 2015 Q3 | 16.24 Billion USD | -4.78% |
| 2014 Q1 | 5.07 Billion USD | 0.5% |
| 2014 Q4 | 4.51 Billion USD | -0.38% |
| 2014 Q3 | 4.52 Billion USD | -10.64% |
| 2014 Q2 | 5.06 Billion USD | -0.12% |
| 2014 FY | 4.51 Billion USD | -10.64% |
| 2013 FY | 5.04 Billion USD | -6.4% |
| 2013 Q4 | 5.04 Billion USD | -20.72% |
| 2013 Q3 | 6.36 Billion USD | 0.14% |
| 2013 Q2 | 6.35 Billion USD | -0.44% |
| 2013 Q1 | 6.38 Billion USD | 18.42% |
| 2012 Q1 | 2.4 Billion USD | -0.33% |
| 2012 FY | 5.39 Billion USD | 123.83% |
| 2012 Q4 | 5.39 Billion USD | 124.67% |
| 2012 Q3 | 2.4 Billion USD | 0.29% |
| 2012 Q2 | 2.39 Billion USD | -0.33% |
| 2011 Q3 | 2.39 Billion USD | 0.08% |
| 2011 Q4 | 2.4 Billion USD | 0.58% |
| 2011 Q1 | 2.4 Billion USD | 0.04% |
| 2011 Q2 | 2.39 Billion USD | -0.37% |
| 2011 FY | 2.4 Billion USD | 0.33% |
| 2010 Q2 | 2.35 Billion USD | -1.01% |
| 2010 FY | 2.4 Billion USD | 2.13% |
| 2010 Q1 | 2.37 Billion USD | 1.19% |
| 2010 Q4 | 2.4 Billion USD | 1.39% |
| 2010 Q3 | 2.36 Billion USD | 0.55% |
| 2009 Q4 | 2.35 Billion USD | 0.13% |
| 2009 FY | 2.35 Billion USD | 65.58% |
| 2009 Q1 | 2.41 Billion USD | 70.22% |
| 2009 Q2 | 2.34 Billion USD | -3.02% |
| 2009 Q3 | 2.34 Billion USD | 0.17% |
| 2008 Q2 | 727.8 Million USD | -37.61% |
| 2008 FY | 1.41 Billion USD | 61.63% |
| 2008 Q1 | 1.16 Billion USD | 32.78% |
| 2008 Q3 | 1.13 Billion USD | 56.13% |
| 2008 Q4 | 1.41 Billion USD | 24.96% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | 878.5 Million USD | 0.0% |
| 2007 FY | 878.5 Million USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2002 FY | - USD | -100.0% |
| 2002 Q3 | - USD | -100.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | 689 Million USD | 56.34% |
| 2002 Q2 | 104.4 Million USD | -84.85% |
| 2001 Q4 | 440.7 Million USD | 23.17% |
| 2001 Q3 | 357.8 Million USD | 10.16% |
| 2001 Q2 | 324.8 Million USD | -29.58% |
| 2001 FY | 440.7 Million USD | 0.0% |
| 2001 Q1 | 461.2 Million USD | 0.0% |
| 2000 Q1 | 98 Million USD | 0.0% |
| 2000 Q2 | 7.1 Million USD | -92.76% |
| 2000 Q3 | - USD | -100.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 Q1 | 100 Million USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q2 | - USD | -100.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | 35 Million USD | 0.0% |
| 1998 Q2 | - USD | -100.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1997 Q1 | 42 Million USD | 0.0% |
| 1997 Q2 | - USD | -100.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q1 | 77.3 Million USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1995 Q1 | 35 Million USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q2 | - USD | -100.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 Q2 | - USD | -100.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | 13 Million USD | 0.0% |
| 1993 Q1 | 119.1 Million USD | 420.09% |
| 1993 Q4 | - USD | -100.0% |
| 1993 Q3 | 8.8 Million USD | -36.69% |
| 1993 FY | - USD | -100.0% |
| 1993 Q2 | 13.9 Million USD | -88.33% |
| 1992 FY | 22.9 Million USD | -82.0% |
| 1992 Q1 | 122.7 Million USD | -3.54% |
| 1992 Q2 | 118.8 Million USD | -3.18% |
| 1992 Q3 | 118.8 Million USD | 0.0% |
| 1992 Q4 | 22.9 Million USD | -80.72% |
| 1991 Q3 | 134.8 Million USD | 0.0% |
| 1991 Q1 | 146.5 Million USD | -2.27% |
| 1991 FY | 127.2 Million USD | -15.14% |
| 1991 Q2 | 134.8 Million USD | -7.99% |
| 1991 Q4 | 127.2 Million USD | -5.64% |
| 1990 Q4 | 149.9 Million USD | 1.01% |
| 1990 FY | 149.9 Million USD | -2.03% |
| 1990 Q3 | 148.4 Million USD | 0.0% |
| 1990 Q2 | 148.4 Million USD | -0.93% |
| 1990 Q1 | 149.8 Million USD | -2.09% |
| 1989 FY | 153 Million USD | -13.12% |
| 1989 Q4 | 153 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -26049.551% |
| Dynavax Technologies Corporation | 256.91 Million USD | -3618.754% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -22906.719% |
| Perrigo Company plc | 4.07 Billion USD | -134.546% |
| Illumina, Inc. | 2.26 Billion USD | -322.37% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 72.638% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -955300.0% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 32.865% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -5398.61% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -253.472% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -35298.296% |
| Waters Corporation | 2.35 Billion USD | -305.602% |
| Biogen Inc. | 7.33 Billion USD | -30.195% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -24973.483% |
| Evolus, Inc. | 126.54 Million USD | -7449.824% |
| Adicet Bio, Inc. | 17.7 Million USD | -53868.254% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -22032.648% |
| bluebird bio, Inc. | 330.32 Million USD | -2792.294% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -1666.162% |
| FibroGen, Inc. | 170.45 Million USD | -5504.998% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -249.324% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -45647.433% |
| Homology Medicines, Inc. | 44.05 Million USD | -21587.02% |
| Geron Corporation | 85.89 Million USD | -11022.365% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | -298.413% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -2046.682% |
| Myriad Genetics, Inc. | 145 Million USD | -6488.966% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -758153.968% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -8182.905% |
| Zoetis Inc. | 6.8 Billion USD | -40.438% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -216937.71% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -340.73% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | -742.597% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | -1081.841% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -26202.893% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | -557.292% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -16408.847% |
| Verastem, Inc. | 41.55 Million USD | -22890.11% |
| Nektar Therapeutics | 230.4 Million USD | -4046.683% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -5026.307% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -310700.26% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | -583.988% |
| OPKO Health, Inc. | 326.56 Million USD | -2825.613% |
| Exelixis, Inc. | 189.94 Million USD | -4929.904% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -2130.159% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -6327052.318% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -6802.73% |
| Imunon, Inc. | 1.13 Million USD | -838490.249% |
| Blueprint Medicines Corporation | 774.12 Million USD | -1134.172% |
| Insmed Incorporated | 1.2 Billion USD | -693.526% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -537.253% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -16664.933% |
| TG Therapeutics, Inc. | 110.79 Million USD | -8523.133% |
| Incyte Corporation | 38.28 Million USD | -24853.64% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -988.775% |